BR0209563A - ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente - Google Patents

ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente

Info

Publication number
BR0209563A
BR0209563A BR0209563-7A BR0209563A BR0209563A BR 0209563 A BR0209563 A BR 0209563A BR 0209563 A BR0209563 A BR 0209563A BR 0209563 A BR0209563 A BR 0209563A
Authority
BR
Brazil
Prior art keywords
nucleic acid
modulate
methods
patient
hbm
Prior art date
Application number
BR0209563-7A
Other languages
English (en)
Inventor
Kristina Allen
Anthony Anisowicz
James R Graham
Arturo Morales
Paul J Yaworsky
Wei Liu
Original Assignee
Genome Theraupeutics Corp
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genome Theraupeutics Corp, Wyeth Corp filed Critical Genome Theraupeutics Corp
Publication of BR0209563A publication Critical patent/BR0209563A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

"áCIDO NUCLEICO, POLIPEPTìDEO, VETOR, CéLULA, ANTICORPO, MéTODOS DE DIAGNOSTICAR UM FENóTIPO E UM PACIENTE COMO EXPRESSANDO UM áCIDO NUCLEICO E DE IDENTIFICAR AGENTES QUE MODULAM A ATIVIDADE DE UM áCIDO NUCLEICO E DE UMA PROTEìNA E LRP5, LRP6 OU HBM E COMPOSTOS QUE MODULAM A INTERAçãO DE Dkk COM O CAMINHO DE SINALIZAçãO Wnt, COMPOSIçãO PARA MODULAR A MASSA óSSEA E/OU OS NìVEIS DE LIPìDEO EM UM PACIENTE, ANIMAL TRANSGêNICO, EMBRIãO E MODELO DE ANIMAL, E, AGENTE". A presente invenção diz respeito a métodos e materiais usados para expressar um polipeptídeo como HBM derivado de HBM, LRP5 ou LRP6 em células de animal e animais transgênicos. A presente invenção também diz respeito aos animais transgênicos que expressam os polipeptídeos como HBM. A invenção fornece ácidos nucleicos, incluindo seq³ências codificadoras, iniciadores de oligonucleotídeo e sondas, proteínas, vetores de clonagem, vetores de expressão, hospedeiros transformados, métodos de desenvolver composições farmacêuticas, métodos de identificar moléculas envolvidas no desenvolvimento ósseo e métodos de diagnosticar e tratar doenças envolvidas no desenvolvimento ósseo e na modulação de lipídeo. Em formas de realização preferidas, a presente invenção está direcionada a métodos para tratar, diagnosticar e prevenir a osteoporose.
BR0209563-7A 2001-05-11 2002-05-13 ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente BR0209563A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29007101P 2001-05-11 2001-05-11
US29131101P 2001-05-17 2001-05-17
US35305802P 2002-02-01 2002-02-01
US36129302P 2002-03-04 2002-03-04
PCT/US2002/014877 WO2002092000A2 (en) 2001-05-11 2002-05-13 Hbm variants that modulate bone mass and lipid levels

Publications (1)

Publication Number Publication Date
BR0209563A true BR0209563A (pt) 2004-12-07

Family

ID=27501520

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0209563-7A BR0209563A (pt) 2001-05-11 2002-05-13 ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
BR0209564-5A BR0209564A (pt) 2001-05-11 2002-05-13 Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0209564-5A BR0209564A (pt) 2001-05-11 2002-05-13 Animal transgênico, embrião, camundongo transgênico, modelo animal para o estudo da modulação da densidade óssea, célula isolada, ácido nucleico para marcar o gene pela recombinação homóloga, e, métodos para estudar determinantes da massa óssea, para estudar moduladores de massa óssea, para estudar a massa óssea, para estudar um efeito hbm sobre os distúrbios ósseos, para identificar marcadores substitutos da formação/reabsorção ósseas, para estudar efeitos de hbm sobre os distúrbios cardìacos, para avaliar tratamentos cárdio-protetores quanto aos efeitos de modulação da massa óssea, para modular a densidade óssea, para produzir um camundongo transgênico e para identificar genes associados com a massa óssea

Country Status (7)

Country Link
US (2) US7416849B2 (pt)
EP (2) EP1401269A4 (pt)
JP (3) JP2004537289A (pt)
AU (2) AU2002316095A1 (pt)
BR (2) BR0209563A (pt)
CA (2) CA2446859A1 (pt)
WO (2) WO2002092764A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
WO2001092891A2 (en) * 2000-05-26 2001-12-06 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
CA2446859A1 (en) 2001-05-11 2002-11-21 Wyeth Transgenic animal model of bone mass modulation
US7514594B2 (en) * 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
CA2446582A1 (en) * 2001-05-17 2002-11-21 Genome Therapeutics Corporation Reagents and methods for modulating dkk-mediated interactions
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
FR2856410B1 (fr) * 2003-06-20 2007-06-15 Integragen Sa Methodes de preparation de puces genetiques et utilisations
WO2005048913A2 (en) * 2003-11-24 2005-06-02 Gunnar Westin Mutant lrp5/6 wnt-signaling receptors in cancer diagnosis, prognosis and treatment
ES2427177T3 (es) * 2004-04-27 2013-10-29 Galapagos N.V. Métodos, agentes y ensayos de detección de compuestos para inducir diferenciación de células de mamífero no diferenciadas para dar lugar a osteoblastos
EP2423326B1 (en) * 2004-05-07 2014-01-08 Celera Corporation Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
EP2336177A1 (en) * 2004-08-04 2011-06-22 Amgen, Inc Antibodies to DKK-1
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
HUE060822T2 (hu) 2006-12-29 2023-04-28 Ossifi Mab Llc Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
DK2567709T3 (en) 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
US8716243B2 (en) * 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
EP2286240B1 (en) * 2008-06-03 2016-01-06 Université de Liège Biomarker for osteoarthritis and use thereof
US20110197290A1 (en) 2010-02-11 2011-08-11 Fahrenkrug Scott C Methods and materials for producing transgenic artiodactyls
AU2011232514A1 (en) 2010-03-24 2012-08-30 Genentech, Inc. Anti-LRP6 antibodies
US9428583B2 (en) 2010-05-06 2016-08-30 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
TW201323442A (zh) 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
EP2858486A4 (en) * 2012-06-12 2016-04-13 Hoffmann La Roche METHODS AND COMPOSITIONS FOR GENERATING ALLLETS WITH CONDITIONAL INACTIVATION
US8959241B2 (en) * 2012-07-23 2015-02-17 Adobe Systems Incorporated Method and apparatus for performing server-side splicing for live streaming media
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
WO2015089074A1 (en) 2013-12-09 2015-06-18 Baylor College Of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US20190218306A1 (en) * 2018-01-18 2019-07-18 Nalini M. Rajamannan Method of inhibiting ectopic calcification

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1997012903A1 (en) 1995-10-04 1997-04-10 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US6555654B1 (en) * 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
CA2286313C (en) * 1997-04-15 2011-01-11 The Wellcome Trust Limited As Trustee To The Wellcome Trust Novel ldl-receptor
BE1011331A6 (fr) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
JP2002506873A (ja) 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
CA2370441A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 50 human secreted proteins
NZ521769A (en) * 2000-04-05 2004-12-24 Genome Therapeutics Corp The high bone mass gene of 11q13.3
WO2001092891A2 (en) 2000-05-26 2001-12-06 Genome Therapeutics Corporation Regulating lipid levels via the zmax1 or hbm gene
CA2411978A1 (en) * 2000-06-21 2001-12-27 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
EP1313753A4 (en) 2000-08-18 2004-09-15 Proskelia REGULATOR GENES AND USEABLE SYSTEM FOR THE DIAGNOSIS AND THERAPY OF THE OSTEOPOROSIS
CA2446859A1 (en) 2001-05-11 2002-11-21 Wyeth Transgenic animal model of bone mass modulation
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
DE102007020878B4 (de) 2007-05-04 2020-06-18 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Verfahren zur Prüfung von Umströmungsgeräuschen

Also Published As

Publication number Publication date
US7416849B2 (en) 2008-08-26
JP2004537289A (ja) 2004-12-16
AU2002308681A1 (en) 2002-11-25
WO2002092000A2 (en) 2002-11-21
EP1483288A2 (en) 2004-12-08
JP2005511002A (ja) 2005-04-28
WO2002092764A2 (en) 2002-11-21
EP1483288A4 (en) 2005-09-21
WO2002092764A3 (en) 2003-12-24
CA2446859A1 (en) 2002-11-21
EP1401269A4 (en) 2005-09-28
AU2002316095A1 (en) 2002-11-25
US20090136507A1 (en) 2009-05-28
WO2002092000A3 (en) 2004-10-07
EP1401269A2 (en) 2004-03-31
US20050070699A1 (en) 2005-03-31
BR0209564A (pt) 2004-10-26
JP2011004744A (ja) 2011-01-13
CA2446821A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
BR0209563A (pt) ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
Bragulla et al. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia
Gilmore et al. Phorbol ester and diacylglycerol induce protein phosphorylation at tyrosine
Mead et al. BMP-4-responsive regulation of dorsal–ventral patterning by the homeobox protein Mix. 1
Beall et al. The small heat shock-related protein, HSP20, is phosphorylated on serine 16 during cyclic nucleotide-dependent relaxation
BR0309126A (pt) Métodos para tratar condições relacionadas com tweak
Bernstein et al. Fine tuning a molecular motor: the location of alternative domains in the Drosophila myosin head
Demmer et al. Molecular cloning of ERp29, a novel and widely expressed resident of the endoplasmic reticulum
BRPI0411020A (pt) perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
KR100404011B1 (ko) 세포-주기조절단백질및그것의사용방법
EA006603B1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
BR0209836A (pt) Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk
ATE302274T1 (de) Methoden zur bestimmung von komponenten zur modulation des körpergewichts
Shoeman et al. Calpains and the cytoskeleton
Scott et al. Homeobox genes and skin development: a review
Lanske et al. Parathyroid hormone-related peptide (PTHrP) and parathyroid hormone (PTH)/PTHrP receptor
Dong et al. Proteomic profiling of stem cell tissues during regeneration of deer antler: A model of mammalian organ regeneration
Tole et al. FORSE-1: a positionally regulated epitope in the developing rat central nervous system
de Jong et al. Heat shock response of the rat lens.
Kornsuthisopon et al. Wnt signaling in dental pulp homeostasis and dentin regeneration
Detrich 3rd et al. Heterogeneity and structure of brain tubulins from cold-adapted Antarctic fishes. Comparison to brain tubulins from a temperate fish and a mammal.
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
BR0017197A (pt) Sequência de ácido nucleico, sequência de aminoácido, vetor de clonagem replicativo, célula hospedeira isolada vetor de expressão, métodos para testar uma substância como um agente terapêutico para modulação óssea em um hospedeiro, para identificar uma molécula e uma proteìna candidata envolvidas na modulação óssea, para testar quanto a atividade de hbm, para desenvolvimento farmacêutico para o tratamento de distúrbios do desenvolvimento ósseo, para tratar um distúrbio do desenvolvimento ósseo em um animal, para alterar o desenvolvimento ósseo em um hospedeiro, para tratar a osteoporose, para avaliar diagnóstico para uma predisposição genética a um distúrbio do desenvolvimento ósseo, para identificar uma predisposição genética para distúrbios do desenvolvimento ósseo, para expressar a proteìna de hbm em tecido ósseo, para amplificar um polimorfismo de nucleotìdeo, para identificar um elemento regulador de um gene de hbm e para modular densidade óssea em um paciente, ensaio de diagnóstico para distúrbios do desenvolvimento ósseo, cromossoma artificial bacteriano, segmento de ácido nucleico isolado, ácido nucleico, e, polipeptìdeo.
Azim et al. Human erythrocyte dematin and protein 4.2 (pallidin) are ATP binding proteins
Burns et al. Role of cysteine 41 of the A subunit of pertussis toxin

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: WYETH (US) , OSCIENT PHARMACEUTICALS CORPORATION (

Free format text: ALTERADO DE: GENOME THERAUPEUTICS CORPORATION

B25G Requested change of headquarter approved

Owner name: WYETH (US) , OSCIENT PHARMACEUTICALS CORPORATION (

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070045970/RJ DE 11/04/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained